Back to Search
DAVID SOLIT, MD
MD
Medical Oncology Physician
NPI: 1578534285IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
210115(NY)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
PERELMAN SCHOOL OF MED AT THE UNIVERSITY OF PENNSYLVANIA
Class of 1995
Research & Publications (20)
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
PMID 19088048·Clin Cancer Res·2008
3-trial
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition.
PMID 18056475·Cancer Res·2007
7-preclinical
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
PMID 17363532·Clin Cancer Res·2007
3-trial
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.
PMID 15756024·Clin Cancer Res·2005
7-preclinical
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
PMID 14584065·Cancer·2003
3-trial
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
PMID 12727831·Cancer Res·2003
7-preclinical
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
PMID 12006510·Clin Cancer Res·2002
7-preclinical
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
PMID 19478061·Proc Natl Acad Sci U S A·2009
8-other
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
PMID 19487299·Cancer Res·2009
8-other
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
PMID 19364960·J Clin Oncol·2009
3-trial
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.
PMID 19251651·Proc Natl Acad Sci U S A·2009
7-preclinical
PIK3CA mutation associates with improved outcome in breast cancer.
PMID 19671852·Clin Cancer Res·2009
8-other
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
PMID 19047285·J Clin Oncol·2009
3-trial
Therapeutic strategies for inhibiting oncogenic BRAF signaling.
PMID 18644254·Curr Opin Pharmacol·2008
6-review
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
PMID 18974395·Mol Cancer Ther·2008
8-other
Genetic predictors of MEK dependence in non-small cell lung cancer.
PMID 19010912·Cancer Res·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1275 YORK AVE
NEW YORK, NY 10021 - Phone
- (212) 639-2000
Quick Facts
- NPI
- 1578534285
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 31
- Publications
- 20
Are you this provider?
Claim Your Profile